| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 79 |
| 1 | PEMBROLIZUMAB | 52 |
| 2 | IPILIMUMAB | 47 |
| 3 | CARBOPLATIN | 30 |
| 4 | PACLITAXEL | 26 |
| 5 | PANTOPRAZOLE | 22 |
| 6 | ATEZOLIZUMAB | 19 |
| 7 | PACLITAXEL (AIBUMIN-BOUND) | 19 |
| 8 | HYDROCORTISONE | 18 |
| 9 | HYDROCORTISONE CREAM | 17 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DEMECLOCYCLINE | 1 | 0.0044 |
| 1 | NAFCILLIN SODIUM | 3 | 0.0033 |
| 2 | CEFTAROLINE FOSAMIL | 2 | 0.0024 |
| 3 | TREMELIMUMAB | 7 | 0.0016 |
| 4 | TALIMOGENE LAHERPAREPVEC | 2 | 0.0013 |
| 5 | HYDRALAZINE HYDROCHLORIDE | 3 | 0.0011 |
| 6 | IPILIMUMAB | 47 | 0.0011 |
| 7 | ACETAMINOPHEN AND DIPHENHYDRAMINE HCL | 3 | 0.0009 |
| 8 | NIVOLUMAB | 79 | 0.0008 |
| 9 | OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE | 1 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 149 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 54 |
| 2 | Corticosteroid [EPC] | 39 |
| 3 | Platinum-based Drug [EPC] | 33 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 28 |
| 5 | Microtubule Inhibitor [EPC] | 26 |
| 6 | beta-Adrenergic Blocker [EPC] | 19 |
| 7 | Benzodiazepine [EPC] | 17 |
| 8 | Platelet Aggregation Inhibitor [EPC] | 16 |
| 9 | Loop Diuretic [EPC] | 15 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 149 | 0.0015 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 54 | 0.0011 |
| 2 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 12 | 0.0006 |
| 4 | Glinide [EPC] | 4 | 0.0004 |
| 5 | CD38-directed Cytolytic Antibody [EPC] | 2 | 0.0003 |
| 6 | Plasma Volume Expander [EPC] | 1 | 0.0003 |
| 7 | Antimalarial [EPC] | 3 | 0.0003 |
| 8 | Antiprotozoal [EPC] | 3 | 0.0003 |
| 9 | Phenothiazine [EPC] | 8 | 0.0003 |